Clinical trials: Portal Vein Thrombosis
Hepatic Encephalopathy
ETOS: Minimal Hepatic Encephalopathy in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study
The aim of the study is: Epidemiological/observational: investigating the presence of neuropsychological and electrophysiological alterations, suggesting a condition of minimal hepatic encephalopathy(and its behavioral…
- Trial name
- ETOS (NCT01798329)
- Testing
- probiotic VSL#3
- Where
- 2 sites in Italy
- Volunteers
- 50 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII
Hepatocellular Carcinoma Non-resectable
Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT
This study was a prospective, single-arm, single-center, phase II exploratory clinical study. To investigate the efficacy and safety of radiotherapy combined with sintilimab and bevacizumab biosimilar in the treatment of…
- Trial name
- NCT05530785
- Testing
- radiotherapy combined with sintilimab and bevacizumab biosimilar
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Yongchang Zhang
Decompensated Cirrhosis, Portal Vein Thrombosis
Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis
Portal vein thrombosis (PVT) refers to an obstruction in the trunk of the portal vein. It can extend downstream to the portal branches, or upstream to the splenic and/or the mesenteric veins.
- Conditions
- Decompensated Cirrhosis, Portal Vein Thrombosis, Bleeding Varices
- Trial name
- NCT01326949
- Testing
- Transjugular intrahepatic portosystemic shunt (TIPS), ET+NSBB
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Air Force Military Medical University, China
Hepatocellular Carcinoma, Portal Vein Tumor Thrombosis
Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis
The proposed study is an open-label, single-center, single arm phase 1b study to evaluate the safety and efficacy of radiotherapy plus sintilimab for HCC with PVTT.
- Trial name
- NCT04104074
- Testing
- Radiotherapy, Sintilimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Portal Hypertension, Portal Vein Thrombosis
Preemptive TIPS for Variceal Bleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis
Portal vein thrombosis (PVT) can lead to a further increase in portal venous pressure and increase the risk of rebleeding. Whether patients with acute esophagogastric variceal bleeding with occlusive PVT benefit from preemptive…
- Conditions
- Portal Hypertension, Portal Vein Thrombosis, Esophageal Varix Bleeding, Portosystemic Shunt
- Trial name
- NCT06122753
- Testing
- preemptive TIPS, standard second prophylaxis
- Where
- China
- Volunteers
- 120 people
- Sponsor
- West China Hospital
Portal Vein Thrombosis
Efficacy and Safety of Acenocoumarol for Treatment of Nontumor Portal Vein Thrombosis in Cirrhosis of Liver
After successful screening the cases of cirrhosis of liver irrespective of the etiology who have non tumor portal vein thrombosis will be enrolled.
- Trial name
- NCT01631877
- Testing
- Enoxaparin with acenocoumarol
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India
Neutrophil Extracellular Trap Formation, Portal Vein Thrombosis
Analysis of Neutrophil Extracellular Traps in Hypercoagulability and Portal Vein Thrombosis in Liver Cirrhosis Patients
The aim of this study was to investigate whether NETs markers can enhance procoagulant activity and predict portal vein thrombosis in patients with live cirrhosis, so as to establish a novel predictor to guide clinical…
- Conditions
- Neutrophil Extracellular Trap Formation, Portal Vein Thrombosis, Liver Cirrhosis
- Trial name
- NCT05012501
- Testing
- test NETs markers
- Where
- China
- Volunteers
- 79 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Hepatocellular Carcinoma
TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT.
Hepatocellular carcinoma (HCC) patients with Vp4 [main trunk] portal vein tumor thrombosis (PVTT) face a significantly poor prognosis, and current treatment options provide limited benefits.
- Trial name
- NCT06669377
- Where
- China
- Volunteers
- 444 people
- Sponsor
- Zhongda Hospital
Biliary Tract Neoplasms, Pancreatic Neoplasm
Portal Vein Stenting for Malignant Obstruction: Feasibility, Safety, and Clinical Outcomes
Introduction: Pre-hepatic portal hypertension of malignant origin can lead to severe complications such as refractory ascites or gastrointestinal bleeding, significantly impairing patients' quality of life.
- Conditions
- Biliary Tract Neoplasms, Pancreatic Neoplasm, Portal Hypertension, Portal Vein Thrombosis
- Trial name
- NCT07252570
- Testing
- Transhepatic portal vein stent implantation
- Where
- France
- Volunteers
- 63 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Hepatocellular Carcinoma, Radiotherapy, Sorafenib
Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma
This is a single-arm phase II clinical trial to investigate the efficacy and toxicity of concurrent sorafenib and intensity-modulated radiotherapy (IMRT) for advanced hepatocellular carcinoma with portal vein or hepatic vein…
- Trial name
- SIRAHCC (NCT03535259)
- Testing
- concurrent sorafenib and IMRT, followed sorafenib maintenance
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Unresectable Hepatocellular Cancer, Portal Vein Tumor Thrombus
Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus
This study aims to evaluate the efficacy and safety of sorafenib plus toripalimab for unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT).
- Trial name
- STUHCCPVTT (NCT04069949)
- Testing
- sorafenib; toripalimab
- Volunteers
- 39 people
- Sponsor
- Sichuan University
IRE
IRE After Targeted Immunotherapy in HCC With Portal Vein Tumor Thrombus
This is a prospective, randomized, controlled, exploratory Phase II clinical study. Approximately 60 eligible patients with hepatocellular carcinoma and portal vein tumor thrombus who have received three cycles of…
- Trial name
- NCT07799922
- Testing
- IRE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Extrahepatic Portal Vein Obstruction (EHPVO), Thrombophilia
Hematological Disorders in EHPVO Patients
This study focuses on patients who have a condition called extrahepatic portal vein obstruction (EHPVO), where a blood clot blocks the portal vein outside the liver.
- Conditions
- Extrahepatic Portal Vein Obstruction (EHPVO), Thrombophilia, Myeloproliferative Neoplasms (MPN), Antiphospholipid Syndrome (APS)
- Trial name
- EHPVO-HEM (NCT07108023)
- Testing
- No intervention (Observational Study)
- Volunteers
- 115 people
- Sponsor
- Rahab Nady
Hepatocellular Carcinoma
Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy.
Hepatocellular carcinoma is prone to invade the portal vein and form portal vein thrombosis, and patients in this period are directly included in the advanced stages, i.e. Barcelona clinical liver cancer stage C.
- Trial name
- NCT06248528
- Testing
- Liver resection, Locoregional therapy
- Where
- China
- Volunteers
- 1,076 people
- Sponsor
- Chen Xiaoping
Hepatocellular Carcinoma
A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection
To compare the impact on recurrence risk of adjuvant Sintilimab (a recombinant fully human anti-PD-1 monoclonal antibody) plus Lenvatinib for patients with hepatocellular carcinoma and portal vein tumor thrombus (PVTT ) after…
- Trial name
- NCT06089382
- Testing
- Sintilimab, Lenvatinib, Transarterial Chemoembolization (TACE)
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Tongji Hospital
Liver Cirrhosis, Portal Vein
Effect of Portal Vein Thrombosis on the Prognosis of Liver Cirrhosis
The prevalence of portal vein thrombosis (PVT) in patients with liver cirrhosis is 5-20%. Current evidence regarding the effect of portal vein thrombosis on the prognosis of cirrhotic patients remains under debate.
- Conditions
- Liver Cirrhosis, Portal Vein, Venous Thrombosis, Varicose Veins
- Trial name
- NCT02335580
- Testing
- Somatostatin and its analogs, Endoscopic sclerotherapy, endoscopic variceal ligation, endoscopic tissue glue injection
- Where
- China
- Volunteers
- 475 people
- Sponsor
- General Hospital of Shenyang Military Region
Liver Cirrhosis, Portal Vein Thrombosis
Portal Vein Thrombosis Relevance on Liver Cirrhosis: Italian Venous Thrombotic Events Registry
The portal vein thrombosis (PVT) can complicate medical conditions like liver cirrhosis (LC), neoplasms, myeloproliferative diseases, thrombophilic genotypes, infections, inflammatory diseases, trauma and surgery.
- Trial name
- PRO-LIVER (NCT01470547)
- Where
- 2 sites in Italy
- Volunteers
- 753 people
- Sponsor
- University of Roma La Sapienza
Hepatocellular Carcinoma With PVTT
Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis
The treatment for Hepatocellular Carcinoma (HCC) with Portal Vein Tumor Thrombosis (PVTT) is still controversial, and there is no universally agreed protocol for its treatment.
- Trial name
- NCT01350206
- Testing
- hepatic resection, TACE
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma Non-resectable
TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT
This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib and iodion-125 seeds brachytherapy (TACE-Len-I) compared with TACE combined with lenvatinib (TACE-Len)…
- Trial name
- NCT04967495
- Testing
- TACE combined with lenvatinib and iodion-125 seeds brachytherapy, TACE combined with lenvatinib
- Where
- China
- Volunteers
- 171 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Portal Vein Thrombosis, Cirrhosis
Indicators Affecting PVT Recanalization
This is a retrospective-prospective study conducted at Zhongshan Hospital, Fudan University, to explore portal vein thrombosis (PVT) in patients with cirrhosis and gastroesophageal varices (GEV).
- Conditions
- Portal Vein Thrombosis, Cirrhosis, Portal Hypertension Related to Cirrhosis, Portal Hypertension, Noncirrhotic
- Trial name
- NCT07473375
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Shanghai Zhongshan Hospital